- Home
- AIP vs CRVS Comparison
AIP vs CRVS Comparison
Compare AIP & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIP
- CRVS
- Stock Information
- Founded
- AIP 2003
- CRVS 2014
- Country
- AIP United States
- CRVS United States
- Employees
- AIP N/A
- CRVS N/A
- Industry
- AIP Semiconductors
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- AIP Technology
- CRVS Health Care
- Exchange
- AIP Nasdaq
- CRVS Nasdaq
- Market Cap
- AIP 412.9M
- CRVS 459.0M
- IPO Year
- AIP 2021
- CRVS 2016
- Fundamental
- Price
- AIP $12.95
- CRVS $6.72
- Analyst Decision
- AIP Strong Buy
- CRVS Strong Buy
- Analyst Count
- AIP 3
- CRVS 3
- Target Price
- AIP $15.00
- CRVS $13.00
- AVG Volume (30 Days)
- AIP 682.1K
- CRVS 744.5K
- Earning Date
- AIP 11-04-2025
- CRVS 11-11-2025
- Dividend Yield
- AIP N/A
- CRVS N/A
- EPS Growth
- AIP N/A
- CRVS N/A
- EPS
- AIP N/A
- CRVS N/A
- Revenue
- AIP $63,236,000.00
- CRVS N/A
- Revenue This Year
- AIP $19.05
- CRVS N/A
- Revenue Next Year
- AIP $17.96
- CRVS N/A
- P/E Ratio
- AIP N/A
- CRVS N/A
- Revenue Growth
- AIP 18.64
- CRVS N/A
- 52 Week Low
- AIP $5.46
- CRVS $2.54
- 52 Week High
- AIP $14.58
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- AIP 70.19
- CRVS 58.77
- Support Level
- AIP $9.67
- CRVS $6.76
- Resistance Level
- AIP $14.58
- CRVS $7.39
- Average True Range (ATR)
- AIP 0.74
- CRVS 0.43
- MACD
- AIP 0.36
- CRVS -0.02
- Stochastic Oscillator
- AIP 68.20
- CRVS 55.26
About AIP Arteris Inc.
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).